IDSA to the Public: Get Your COVID-19 Boosters

Tremendous progress has been made in controlling the spread of COVID-19 and curbing its most lethal effects. There are now multiple types of vaccines, therapeutic options and a new vaccine that targets the prevailing, more contagious strain of COVID-19.

Protecting Patient Autonomy and the Provider-Patient Relationship

IDSA and HIVMA strongly oppose government interference in the patient-health care provider relationship and religious refusal laws and regulations that allow health care professionals, employers, systems or insurers to deny access to services based on their own personal religious beliefs.

IDSA Supports Authorization of Bivalent COVID-19 Boosters

IDSA supports decisions by the Food and Drug Administration and the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices to authorize and recommend boosters meant to curb cases of more highly infectious strains of COVID-19.

Statement on NIAID Director Anthony Fauci

IDSA and HIVMA are immensely grateful for Dr. Anthony Fauci’s contributions to the identification, treatment and containment of infectious diseases through his 38 years of leadership of the National Institute of Allergy and Infectious Diseases.

IDSA Honors 175 Distinguished Physicians, Scientists with FIDSA Designation

The nation’s leading infectious diseases professional society, recognizes the distinguished physicians and scientists from the United States and around the world who were elected this year to be Fellows of IDSA.

HIV Providers Call for Policy Reforms to End HIV as an Epidemic

IDSA and HIVMA say that while barriers to ending the HIV epidemic are significant, the goal could be within reach with broad-based policy reforms at the federal, state and local levels.

IDSA on New CDC Changes to Post-COVID-19 Infection Recommendations

Updated recommendations from the Centers for Disease Control and Prevention on masking and isolation post-COVID-19 infection are a positive sign that advances in vaccines and treatments have significantly lowered the risk of severe illness, hospitalization and death from the disease.

Monkeypox Bill Provides Crucial Steps Toward Equitable Access to Testing

IDSA applauds new legislation introduced by Rep. Sean Patrick Maloney (D-NY) to ensure monkeypox testing is available at no cost to the public.

Monkeypox Public Health Emergency Should Grant Flexibility to Expand Treatment and Vaccine Access

IDSA and HIVMA support the Biden Administration’s decision to declare the monkeypox outbreak a public health emergency.

IDSA and HIVMA Applaud New Administration Monkeypox Coordinators, Call for Funding and Improved Vaccine Supply and Access

As monkeypox cases top more than 5,800 across 48 states, there is no time to waste.

Senate Appropriations Bill Provides Boost to Fight Against AMR

IDSA is pleased to see that critical new investments to strengthen the federal fight against antimicrobial resistance were included in the fiscal year 2023 Labor, Health and Human Services appropriations bill released July 28.

IDSA Statement on Increase in Monkeypox Vaccine Supply

Today’s U.S. Department of Health and Human Services announcement that nearly 800,000 additional doses of the monkeypox vaccine are now available for distribution is a welcome development, but much more is urgently needed.